{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T05:22:52Z","timestamp":1783056172693,"version":"3.54.6"},"reference-count":130,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009045","name":"Jagiellonian University Medical College","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100009045","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Tadeusz and Jan O\u015bwiecimski Foundation"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>Triple-negative breast cancer (TNBC), particularly when associated with breast cancer susceptibility gene 1\/2 (BRCA1\/2) alterations or homologous recombination deficiency (HRD), remains therapeutically challenging because DNA repair vulnerabilities coexist with molecular heterogeneity, resistance, and toxicity constraints. This narrative review synthesizes mechanistic, preclinical, clinical, and translational evidence on DNA damage response (DDR)-targeted and synthetic lethality-based strategies in TNBC. We summarize TNBC biological heterogeneity, current biomarker-guided treatment options, mechanisms of poly(ADP-ribose) polymerase (PARP) inhibition and resistance, and emerging DDR targets, including ataxia telangiectasia and Rad3-related\/checkpoint kinase 1 (ATR\/CHK1), WEE1, DNA-dependent protein kinase (DNA-PK), RAD51, DNA polymerase theta (POLQ), neddylation-related pathways, and targeted protein degradation. The review highlights that PARP inhibitors and platinum agents provide clinically validated examples of exploiting HRD in selected populations, whereas most next-generation DDR inhibitors remain preclinical, investigational, or in early clinical trials. Resistance mechanisms, including BRCA reversion, homologous recombination restoration, replication fork stabilization, and checkpoint adaptation, limit durable benefit. Safety, target selectivity, overlapping toxicities, and the lack of standardized functional biomarkers further constrain translation. Future progress will require prospective biomarker validation, dynamic HRD assessment, rational scheduling of combinations, and medicinal chemistry approaches that improve therapeutic index rather than a broad application of DDR inhibition across all TNBC.<\/jats:p>","DOI":"10.3390\/molecules31132303","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T10:41:01Z","timestamp":1782902461000},"page":"2303","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Overcoming Resistance in Triple-Negative Breast Cancer: A Translational Perspective on Next-Generation DNA Damage Response Inhibitors and Synthetic Lethality"],"prefix":"10.3390","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9731-908X","authenticated-orcid":false,"given":"Jakub","family":"Jo\u0144czyk","sequence":"first","affiliation":[{"name":"Department of Medicinal Chemistry, Jagiellonian University Medical College, Medyczna 9, 30-688 Krak\u00f3w, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1448-9826","authenticated-orcid":false,"given":"Anna","family":"Czopek","sequence":"additional","affiliation":[{"name":"Department of Medicinal Chemistry, Jagiellonian University Medical College, Medyczna 9, 30-688 Krak\u00f3w, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulyana","family":"Kvinta","sequence":"additional","affiliation":[{"name":"Students Scientific Group of Drug Discovery, Jagiellonian University Medical College, \u015aw. Anny 12, 31-008 Krak\u00f3w, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-4041-5048","authenticated-orcid":false,"given":"Aleksandra","family":"Skok","sequence":"additional","affiliation":[{"name":"Students Scientific Group of Drug Discovery, Jagiellonian University Medical College, \u015aw. Anny 12, 31-008 Krak\u00f3w, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2510-7237","authenticated-orcid":false,"given":"Agnieszka","family":"Zag\u00f3rska","sequence":"additional","affiliation":[{"name":"Department of Medicinal Chemistry, Jagiellonian University Medical College, Medyczna 9, 30-688 Krak\u00f3w, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,1]]},"reference":[{"key":"ref_1","unstructured":"(2026, March 17). Cancer. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/cancer."},{"key":"ref_2","unstructured":"(2026, June 12). Breast Cancer Types\u2014NCI, Available online: https:\/\/www.cancer.gov\/types\/breast\/breast-cancer-types."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/S0140-6736(16)31891-8","article-title":"Breast Cancer","volume":"389","author":"Harbeck","year":"2017","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41698-025-01209-9","article-title":"HER2 Expression in Breast Cancer: Evidence Gaps and Challenges","volume":"10","author":"Atallah","year":"2025","journal-title":"npj Precis. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1158\/2159-8290.CD-25-0647","article-title":"Trastuzumab Deruxtecan Resistance via Loss of HER2 Expression and Binding","volume":"16","author":"Chen","year":"2026","journal-title":"Cancer Discov."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S1470-2045(19)30328-6","article-title":"Trastuzumab Duocarmazine in Locally Advanced and Metastatic Solid Tumours and HER2-Expressing Breast Cancer: A Phase 1 Dose-Escalation and Dose-Expansion Study","volume":"20","author":"Banerji","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1080\/10717544.2022.2069883","article-title":"Disitamab Vedotin: A Novel Antibody-Drug Conjugates for Cancer Therapy","volume":"29","author":"Shi","year":"2022","journal-title":"Drug Deliv."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1200\/JCO.19.02488","article-title":"HER2-Low Breast Cancer: Pathological and Clinical Landscape","volume":"38","author":"Tarantino","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1158\/1078-0432.CCR-14-0432","article-title":"Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-Negative Breast Cancer","volume":"21","author":"Burstein","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13058-020-01296-5","article-title":"Triple-Negative Breast Cancer Molecular Subtyping and Treatment Progress","volume":"22","author":"Yin","year":"2020","journal-title":"Breast Cancer Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1158\/2159-8290.CD-18-1177","article-title":"Insights into Molecular Classifications of Triple-Negative Breast Cancer: Improving Patient Selection for Treatment","volume":"9","author":"Lin","year":"2019","journal-title":"Cancer Discov."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/nrclinonc.2016.66","article-title":"Triple-Negative Breast Cancer: Challenges and Opportunities of a Heterogeneous Disease","volume":"13","author":"Bianchini","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/s41571-018-0001-7","article-title":"Triple-Negative Breast Cancers\u2014A Panoply of Cancer Types","volume":"15","author":"Pareja","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"10232","DOI":"10.1038\/s41467-024-54145-w","article-title":"Spatial Transcriptomics Reveals Substantial Heterogeneity in Triple-Negative Breast Cancer with Potential Clinical Implications","volume":"15","author":"Wang","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e70733","DOI":"10.1002\/mco2.70733","article-title":"Targeted Therapies for Each Subtype of Breast Cancer","volume":"7","author":"Liu","year":"2026","journal-title":"MedComm"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1126\/science.aam7344","article-title":"PARP Inhibitors: Synthetic Lethality in the Clinic","volume":"355","author":"Lord","year":"2017","journal-title":"Science"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/s41591-018-0009-7","article-title":"Carboplatin in BRCA1\/2-Mutated and Triple-Negative Breast Cancer BRCAness Subgroups: The TNT Trial","volume":"24","author":"Tutt","year":"2018","journal-title":"Nat. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1080\/14728222.2022.2170779","article-title":"The Tumor Microenvironment and Triple-Negative Breast Cancer Aggressiveness: Shedding Light on Mechanisms and Targeting","volume":"26","author":"Furukawa","year":"2023","journal-title":"Expert Opin. Ther. Targets"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2097920","DOI":"10.1155\/2024\/2097920","article-title":"Triple-Negative Breast Cancer: Tumor Immunogenicity and Beyond","volume":"2024","author":"Ibrahim","year":"2024","journal-title":"Int. J. Breast Cancer"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1186\/s40364-024-00714-6","article-title":"Tumor Microenvironment and Immunotherapy for Triple-Negative Breast Cancer","volume":"12","author":"Guo","year":"2024","journal-title":"Biomark. Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41571-021-00565-2","article-title":"Treatment Landscape of Triple-Negative Breast Cancer\u2014Expanded Options, Evolving Needs","volume":"19","author":"Bianchini","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","article-title":"Understanding the Tumor Immune Microenvironment (TIME) for Effective Therapy","volume":"24","author":"Binnewies","year":"2018","journal-title":"Nat. Med."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Carvalho, E., Canberk, S., Schmitt, F., and Vale, N. (2025). Molecular Subtypes and Mechanisms of Breast Cancer: Precision Medicine Approaches for Targeted Therapies. Cancers, 17.","DOI":"10.3390\/cancers17071102"},{"key":"ref_24","first-page":"101","article-title":"Prognostic Significance and Molecular Classification of Triple Negative Breast Cancer: A Systematic Review","volume":"21","author":"Dogra","year":"2025","journal-title":"Eur. J. Breast Health"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Zhou, Z., and Zhou, Q. (2025). Immunotherapy Resistance in Triple-Negative Breast Cancer: Molecular Mechanisms, Tumor Microenvironment, and Therapeutic Implications. Front. Oncol., 15.","DOI":"10.3389\/fonc.2025.1630464"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/annonc\/mdz036","article-title":"Genomic Alterations in Breast Cancer: Level of Evidence for Actionability According to ESMO Scale for Clinical Actionability of Molecular Targets (ESCAT)","volume":"30","author":"Condorelli","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of Cancer: New Dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/s41586-023-06461-2","article-title":"Long-Molecule Scars of Backup DNA Repair in BRCA1- and BRCA2-Deficient Cancers","volume":"621","author":"Setton","year":"2023","journal-title":"Nature"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nrc.2015.21","article-title":"BRCAness Revisited","volume":"16","author":"Lord","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/s41420-025-02418-8","article-title":"Perspectives on Cancer Therapy\u2014Synthetic Lethal Precision Medicine Strategies, Molecular Mechanisms, Therapeutic Targets and Current Technical Challenges","volume":"11","author":"Peng","year":"2025","journal-title":"Cell Death Discov."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/s41392-023-01548-8","article-title":"A New Wave of Innovations within the DNA Damage Response","volume":"8","author":"Li","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1038\/s41416-024-02827-z","article-title":"BRCA-Mutated Breast Cancer: The Unmet Need, Challenges and Therapeutic Benefits of Genetic Testing","volume":"131","author":"Arun","year":"2024","journal-title":"Br. J. Cancer"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"4601","DOI":"10.1158\/0008-5472.CAN-20-1830","article-title":"BRCA1 Mutations in Cancer: Coordinating Deficiencies in Homologous Recombination with Tumorigenesis","volume":"80","author":"Krais","year":"2020","journal-title":"Cancer Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.molcel.2023.12.025","article-title":"BRCA2 Promotes Genomic Integrity and Therapy Resistance Primarily through Its Role in Homology-Directed Repair","volume":"84","author":"Lim","year":"2024","journal-title":"Mol. Cell"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.cell.2012.05.036","article-title":"Systematic Functional Prioritization of Protein Posttranslational Modifications","volume":"150","author":"Beltrao","year":"2012","journal-title":"Cell"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/s41571-018-0114-z","article-title":"State-of-the-Art Strategies for Targeting the DNA Damage Response in Cancer","volume":"16","author":"Tang","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1053\/j.seminoncol.2023.08.001","article-title":"PARP1 Roles in DNA Repair and DNA Replication: The Basi(c)s of PARP Inhibitor Efficacy and Resistance","volume":"51","author":"Kanev","year":"2024","journal-title":"Semin. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.trecan.2024.06.008","article-title":"PARPi, BRCA, and Gaps: Controversies and Future Research","volume":"10","author":"Dibitetto","year":"2024","journal-title":"Trends Cancer"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1053\/j.seminoncol.2023.09.005","article-title":"PARP Inhibitors: A Review of the Pharmacology, Pharmacokinetics, and Pharmacogenetics","volume":"51","author":"Zeng","year":"2024","journal-title":"Semin. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"362ps17","DOI":"10.1126\/scitranslmed.aaf9246","article-title":"Laying a Trap to Kill Cancer Cells: PARP Inhibitors and Their Mechanisms of Action","volume":"8","author":"Pommier","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"5588","DOI":"10.1158\/0008-5472.CAN-12-2753","article-title":"Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors","volume":"72","author":"Murai","year":"2012","journal-title":"Cancer Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1007\/s40262-022-01167-6","article-title":"Pharmacokinetics and Pharmacodynamics of PARP Inhibitors in Oncology","volume":"61","author":"Bruin","year":"2022","journal-title":"Clin. Pharmacokinet."},{"key":"ref_43","unstructured":"(2026, April 28). Setting a Trap for PARP1 and PARP2. Available online: https:\/\/bpsbioscience.com\/setting-a-trap-for-parp1-and-parp2."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1158\/2159-8290.CD-19-1485","article-title":"Clinical BRCA1\/2 Reversion Analysis Identifies Hotspot Mutations and Predicted Neoantigens Associated with Therapy Resistance","volume":"10","author":"Pettitt","year":"2020","journal-title":"Cancer Discov."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1038\/s41467-018-03917-2","article-title":"Genome-Wide and High-Density CRISPR-Cas9 Screens Identify Point Mutations in PARP1 Causing PARP Inhibitor Resistance","volume":"9","author":"Pettitt","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/s41571-021-00532-x","article-title":"Understanding and Overcoming Resistance to PARP Inhibitors in Cancer Therapy","volume":"18","author":"Dias","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/s41416-023-02326-7","article-title":"PARP Inhibitors: Enhancing Efficacy through Rational Combinations","volume":"129","author":"Bhamidipati","year":"2023","journal-title":"Br. J. Cancer"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"3636","DOI":"10.1038\/s41467-021-23463-8","article-title":"Pol\u03b8 Inhibitors Elicit BRCA-Gene Synthetic Lethality and Target PARP Inhibitor Resistance","volume":"12","author":"Zatreanu","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1038\/s41416-021-01405-x","article-title":"Phase 1 Study of the ATR Inhibitor Berzosertib (Formerly M6620, VX-970) Combined with Gemcitabine \u00b1 Cisplatin in Patients with Advanced Solid Tumours","volume":"125","author":"Middleton","year":"2021","journal-title":"Br. J. Cancer"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"5","DOI":"10.32604\/or.2026.071632","article-title":"Next Generation DNA Damage Response Inhibitors: Harnessing Nanocarriers and Tumor Microenvironment for Precision Cancer Therapy","volume":"34","author":"Solomon","year":"2026","journal-title":"Oncol. Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.cell.2013.10.043","article-title":"ATR Prohibits Replication Catastrophe by Preventing Global Exhaustion of RPA","volume":"155","author":"Toledo","year":"2013","journal-title":"Cell"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.molcel.2015.10.040","article-title":"Targeting the DNA Damage Response in Cancer","volume":"60","year":"2015","journal-title":"Mol. Cell"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"3111","DOI":"10.1111\/cas.14565","article-title":"Synthetic Lethality Strategies: Beyond BRCA1\/2 Mutations in Pancreatic Cancer","volume":"111","author":"Hu","year":"2020","journal-title":"Cancer Sci."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"3726","DOI":"10.1038\/s41467-020-17127-2","article-title":"Combining PARP with ATR Inhibition Overcomes PARP Inhibitor and Platinum Resistance in Ovarian Cancer Models","volume":"11","author":"Kim","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1158\/0008-5472.CAN-21-2997","article-title":"ATR Inhibitor AZD6738 (Ceralasertib) Exerts Antitumor Activity as a Monotherapy and in Combination with Chemotherapy and the PARP Inhibitor Olaparib","volume":"82","author":"Wilson","year":"2022","journal-title":"Cancer Res."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ygyno.2022.11.014","article-title":"Elimusertib (BAY1895344), a Novel ATR Inhibitor, Demonstrates in Vivo Activity in ATRX Mutated Models of Uterine Leiomyosarcoma","volume":"168","author":"Harold","year":"2023","journal-title":"Gynecol. Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41523-022-00406-0","article-title":"Phase 1b Study of Berzosertib and Cisplatin in Patients with Advanced Triple-Negative Breast Cancer","volume":"8","author":"Telli","year":"2022","journal-title":"npj Breast Cancer"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"9889","DOI":"10.1021\/acs.jmedchem.8b01187","article-title":"Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent","volume":"61","author":"Foote","year":"2018","journal-title":"J. Med. Chem."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1038\/s41416-023-02436-2","article-title":"A Phase I Study of ATR Inhibitor Gartisertib (M4344) as a Single Agent and in Combination with Carboplatin in Patients with Advanced Solid Tumours","volume":"130","author":"Burris","year":"2024","journal-title":"Br. J. Cancer"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s13058-019-1192-2","article-title":"Prexasertib Treatment Induces Homologous Recombination Deficiency and Synergizes with Olaparib in Triple-Negative Breast Cancer Cells","volume":"21","author":"Mani","year":"2019","journal-title":"Breast Cancer Res."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.tips.2016.06.006","article-title":"Targeting WEE1 Kinase in Cancer","volume":"37","author":"Matheson","year":"2016","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/s41416-024-02745-0","article-title":"ATR, CHK1 and WEE1 Inhibitors Cause Homologous Recombination Repair Deficiency to Induce Synthetic Lethality with PARP Inhibitors","volume":"131","author":"Smith","year":"2024","journal-title":"Br. J. Cancer"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"e57894","DOI":"10.7554\/eLife.57894","article-title":"PTEN and DNA-PK Determine Sensitivity and Recovery in Response to Wee1 Inhibition in Human Breast Cancer","volume":"9","author":"Brunner","year":"2020","journal-title":"eLife"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"3932","DOI":"10.1016\/j.molcel.2022.08.028","article-title":"DNA-PKcs Promotes Fork Reversal and Chemoresistance","volume":"82","author":"Dibitetto","year":"2022","journal-title":"Mol. Cell"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.molcel.2017.05.015","article-title":"ATM, ATR, and DNA-PK: The Trinity at the Heart of the DNA Damage Response","volume":"66","author":"Blackford","year":"2017","journal-title":"Mol. Cell"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ccell.2018.01.019","article-title":"BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination Deficiency","volume":"33","author":"Sun","year":"2018","journal-title":"Cancer Cell"},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Orhan, E., Velazquez, C., Tabet, I., Sardet, C., and Theillet, C. (2021). Regulation of Rad51 at the Transcriptional and Functional Levels: What Prospects for Cancer Therapy?. Cancers, 13.","DOI":"10.3390\/cancers13122930"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.1021\/jm201173g","article-title":"Inhibition of Homologous Recombination in Human Cells by Targeting RAD51 Recombinase","volume":"55","author":"Huang","year":"2012","journal-title":"J. Med. Chem."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"7347","DOI":"10.1093\/nar\/gks353","article-title":"RI-1: A Chemical Inhibitor of RAD51 That Disrupts Homologous Recombination in Human Cells","volume":"40","author":"Budke","year":"2012","journal-title":"Nucleic Acids Res."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ejmech.2019.01.008","article-title":"Rad51\/BRCA2 Disruptors Inhibit Homologous Recombination and Synergize with Olaparib in Pancreatic Cancer Cells","volume":"165","author":"Roberti","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1021\/jm301565b","article-title":"An Optimized RAD51 Inhibitor That Disrupts Homologous Recombination without Requiring Michael Acceptor Reactivity","volume":"56","author":"Budke","year":"2012","journal-title":"J. Med. Chem."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.chembiol.2021.02.006","article-title":"A Small-Molecule Inhibitor of the BRCA2-RAD51 Interaction Modulates RAD51 Assembly and Potentiates DNA Damage-Induced Cell Death","volume":"28","author":"Scott","year":"2021","journal-title":"Cell Chem. Biol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/s41467-025-66694-9","article-title":"Computationally-Designed Aptamers Targeting RAD51-BRCA2 Interaction Impair Homologous Recombination and Induce Synthetic Lethality","volume":"17","author":"Milordini","year":"2026","journal-title":"Nat. Commun."},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Wang, Z., Jia, R., Wang, L., Yang, Q., Hu, X., Fu, Q., Zhang, X., Li, W., and Ren, Y. (2022). The Emerging Roles of Rad51 in Cancer and Its Potential as a Therapeutic Target. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.935593"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"217505","DOI":"10.1016\/j.canlet.2025.217505","article-title":"ZNF251 Haploinsufficiency Confers PARP Inhibitors Resistance in BRCA1-Mutated Cancer Cells through Activation of Homologous Recombination","volume":"613","author":"Li","year":"2025","journal-title":"Cancer Lett."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"P2-05-05","DOI":"10.1158\/1538-7445.SABCS19-P2-05-05","article-title":"Abstract P2-05-05: RAD51 Inhibition Using CYT-0851, Shows Anti-Cancer Activity in Cellular Models of Breast Cancer and Acts Synergistically with PARP Inhibitors","volume":"80","author":"Guy","year":"2020","journal-title":"Cancer Res."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"103738","DOI":"10.1016\/j.dnarep.2024.103738","article-title":"\u201cBridging the DNA Divide\u201d: Understanding the Interplay between Replication- Gaps and Homologous Recombination Proteins RAD51 and BRCA1\/2","volume":"141","author":"Costanzo","year":"2024","journal-title":"DNA Repair"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"5822","DOI":"10.1038\/s41467-024-50158-7","article-title":"PARG Is Essential for Pol\u03b8-Mediated DNA End-Joining by Removing Repressive Poly-ADP-Ribose Marks","volume":"15","author":"Vekariya","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Barszczewska-Pietraszek, G., Drzewiecka, M., Czarny, P., Skorski, T., and \u015aliwi\u0144ski, T. (2022). Pol\u03b8 Inhibition: An Anticancer Therapy for HR-Deficient Tumours. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24010319"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1038\/s41417-024-00815-2","article-title":"Pol\u03b8: Emerging Synthetic Lethal Partner in Homologous Recombination-Deficient Tumors","volume":"31","author":"Mujacic","year":"2024","journal-title":"Cancer Gene Ther."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1038\/s41467-024-46593-1","article-title":"Discovery of a Small-Molecule Inhibitor That Traps Pol\u03b8 on DNA and Synergizes with PARP Inhibitors","volume":"15","author":"Fried","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1038\/s43018-021-00203-x","article-title":"A First-in-Class Polymerase Theta Inhibitor Selectively Targets Homologous-Recombination-Deficient Tumors","volume":"2","author":"Zhou","year":"2021","journal-title":"Nat. Cancer"},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Luo, X., Gao, S., Sun, K., Dong, Z., and Yang, S. (2025). PARP Inhibitors as Radiosensitizers: A Comprehensive Review of Preclinical Evidence and Clinical Applications. Front. Oncol., 15.","DOI":"10.3389\/fonc.2025.1702121"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1093\/annonc\/mdw133","article-title":"Olaparib Monotherapy in Patients with Advanced Relapsed Ovarian Cancer and a Germline BRCA1\/2 Mutation: A Multistudy Analysis of Response Rates and Safety","volume":"27","author":"Matulonis","year":"2016","journal-title":"Ann. Oncol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/S1470-2045(11)70214-5","article-title":"Olaparib in Patients with Recurrent High-Grade Serous or Poorly Differentiated Ovarian Carcinoma or Triple-Negative Breast Cancer: A Phase 2, Multicentre, Open-Label, Non-Randomised Study","volume":"12","author":"Gelmon","year":"2011","journal-title":"Lancet Oncol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1038\/s43018-022-00439-1","article-title":"A Phase II Study of Talazoparib Monotherapy in Patients with Wild-Type BRCA1 and BRCA2 with a Mutation in Other Homologous Recombination Genes","volume":"3","author":"Gruber","year":"2022","journal-title":"Nat. Cancer"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1470-2045(22)00739-2","article-title":"Cisplatin with Veliparib or Placebo in Metastatic Triple-Negative Breast Cancer and BRCA Mutation-Associated Breast Cancer (S1416): A Randomised, Double-Blind, Placebo-Controlled, Phase 2 Trial","volume":"24","author":"Rodler","year":"2023","journal-title":"Lancet Oncol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1200\/jco.2014.32.15_suppl.1019","article-title":"Cisplatin with or without Rucaparib after Preoperative Chemotherapy in Patients with Triple-Negative Breast Cancer (TNBC): Hoosier Oncology Group BRE09-146","volume":"32","author":"Dwadasi","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s10549-015-3616-8","article-title":"SOLTI NeoPARP: A Phase II Randomized Study of Two Schedules of Iniparib plus Paclitaxel versus Paclitaxel Alone as Neoadjuvant Therapy in Patients with Triple-Negative Breast Cancer","volume":"154","author":"Bermejo","year":"2015","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1001\/jamaoncol.2019.1029","article-title":"Open-Label Clinical Trial of Niraparib Combined with Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer","volume":"5","author":"Vinayak","year":"2019","journal-title":"JAMA Oncol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1158\/1078-0432.CCR-21-3045","article-title":"Phase 1b Clinical Trial with Alpelisib plus Olaparib for Patients with Advanced Triple-Negative Breast Cancer","volume":"28","author":"Batalini","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"4714","DOI":"10.1158\/1078-0432.CCR-22-0749","article-title":"Mutational Signature 3 Detected from Clinical Panel Sequencing Is Associated with Responses to Olaparib in Breast and Ovarian Cancers","volume":"28","author":"Batalini","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1158\/1078-0432.CCR-23-2513","article-title":"Phase II DORA Study of Olaparib with or without Durvalumab as a Chemotherapy-Free Maintenance Strategy in Platinum-Pretreated Advanced Triple-Negative Breast Cancer","volume":"30","author":"Tan","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Liu, Y., Wang, W., Yin, R., Zhang, Y., Zhang, Y., Zhang, K., Pan, H., Wang, K., Lou, G., and Li, G. (2023). A Phase 1 Trial of Fuzuloparib in Combination with Apatinib for Advanced Ovarian and Triple-Negative Breast Cancer: Efficacy, Safety, Pharmacokinetics and Germline BRCA Mutation Analysis. BMC Med., 21.","DOI":"10.1186\/s12916-023-03046-8"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1001\/jamaoncol.2022.5074","article-title":"Concurrent Olaparib and Radiotherapy in Patients with Triple-Negative Breast Cancer: The Phase 1 Olaparib and Radiation Therapy for Triple-Negative Breast Cancer Trial","volume":"8","author":"Loap","year":"2022","journal-title":"JAMA Oncol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.ijrobp.2020.09.032","article-title":"Combination of Olaparib and Radiation Therapy for Triple Negative Breast Cancer: Preliminary Results of the RADIOPARP Phase 1 Trial","volume":"109","author":"Loap","year":"2021","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1038\/s41416-021-01664-8","article-title":"Combined PARP and HSP90 Inhibition: Preclinical and Phase 1 Evaluation in Patients with Advanced Solid Tumours","volume":"126","author":"Konstantinopoulos","year":"2021","journal-title":"Br. J. Cancer"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41573-024-01060-w","article-title":"DNA Damage Response Inhibitors in Cancer Therapy: Lessons from the Past, Current Status and Future Implications","volume":"24","author":"Drew","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1038\/nature08467","article-title":"The DNA-Damage Response in Human Biology and Disease","volume":"461","author":"Jackson","year":"2009","journal-title":"Nature"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1158\/2159-8290.CD-16-0860","article-title":"Targeting DNA Repair in Cancer: Beyond PARP Inhibitors","volume":"7","author":"Brown","year":"2017","journal-title":"Cancer Discov."},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Martorana, F., Da Silva, L.A., Sessa, C., and Colombo, I. (2022). Everything Comes with a Price: The Toxicity Profile of DNA-Damage Response Targeting Agents. Cancers, 14.","DOI":"10.3390\/cancers14040953"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1158\/1541-7786.MCR-15-0191-T","article-title":"Mechanistic Dissection of PARP1 Trapping and the Impact on In Vivo Tolerability and Efficacy of PARP Inhibitors","volume":"13","author":"Hopkins","year":"2015","journal-title":"Mol. Cancer Res."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"2489720","DOI":"10.1080\/14756366.2025.2489720","article-title":"Medicinal Chemistry Breakthroughs on ATM, ATR, and DNA-PK Inhibitors as Prospective Cancer Therapeutics","volume":"40","author":"Sharma","year":"2025","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"e2300483","DOI":"10.1200\/PO.23.00483","article-title":"Combining Homologous Recombination-Deficient Testing and Functional RAD51 Analysis Enhances the Prediction of Poly(ADP-Ribose) Polymerase Inhibitor Sensitivity","volume":"8","author":"Korsholm","year":"2024","journal-title":"JCO Precis. Oncol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1093\/annonc\/mdy099","article-title":"RAD51 Foci as a Functional Biomarker of Homologous Recombination Repair and PARP Inhibitor Resistance in Germline BRCA-Mutated Breast Cancer","volume":"29","author":"Cruz","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/s41388-024-03227-6","article-title":"Combination Strategies with PARP Inhibitors in BRCA-Mutated Triple-Negative Breast Cancer: Overcoming Resistance Mechanisms","volume":"44","author":"Jain","year":"2024","journal-title":"Oncogene"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"784","DOI":"10.18632\/oncotarget.27485","article-title":"Both BRCA1-Wild Type and -Mutant Triple-Negative Breast Cancers Show Sensitivity to the NAE Inhibitor MLN4924 Which Is Enhanced upon MLN4924 and Cisplatin Combination Treatment","volume":"11","author":"Misra","year":"2020","journal-title":"Oncotarget"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41523-024-00644-4","article-title":"Targeting Neddylation and Sumoylation in Chemoresistant Triple Negative Breast Cancer","volume":"10","author":"Powell","year":"2024","journal-title":"npj Breast Cancer"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41392-024-01800-9","article-title":"Protein Neddylation and Its Role in Health and Diseases","volume":"9","author":"Zhang","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.molcel.2009.12.024","article-title":"Substrate-Assisted Inhibition of Ubiquitin-like Protein-Activating Enzymes: The NEDD8 E1 Inhibitor MLN4924 Forms a NEDD8-AMP Mimetic In Situ","volume":"37","author":"Brownell","year":"2010","journal-title":"Mol. Cell"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1158\/0008-5472.CAN-12-1729","article-title":"Novel DNA Damage Checkpoints Mediating Cell Death Induced by the NEDD8-Activating Enzyme Inhibitor MLN4924","volume":"73","author":"Blank","year":"2013","journal-title":"Cancer Res."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1089\/ars.2013.5795","article-title":"Targeting Neddylation Pathways to Inactivate Cullin-RING Ligases for Anticancer Therapy","volume":"21","author":"Zhao","year":"2014","journal-title":"Antioxid. Redox Signal."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1038\/s41467-017-01243-7","article-title":"A Potent Small-Molecule Inhibitor of the DCN1-UBC12 Interaction That Selectively Blocks Cullin 3 Neddylation","volume":"8","author":"Zhou","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.bbrc.2016.12.162","article-title":"MLN4924 Suppresses the BRCA1 Complex and Synergizes with PARP Inhibition in NSCLC Cells","volume":"483","author":"Guo","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.molcel.2013.01.006","article-title":"RNF111-Dependent Neddylation Activates DNA Damage-Induced Ubiquitination","volume":"49","author":"Ma","year":"2013","journal-title":"Mol. Cell"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1093\/nar\/gku1384","article-title":"Neddylation Inhibits CtIP-Mediated Resection and Regulates DNA Double Strand Break Repair Pathway Choice","volume":"43","author":"Jimeno","year":"2015","journal-title":"Nucleic Acids Res."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.ccr.2012.02.009","article-title":"Treatment-Emergent Mutations in NAE\u03b2 Confer Resistance to the NEDD8-Activating Enzyme Inhibitor MLN4924","volume":"21","author":"Milhollen","year":"2012","journal-title":"Cancer Cell"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1007\/s10637-020-01055-5","article-title":"A First-in-Human, Phase 1 Study of the NEDD8 Activating Enzyme E1 Inhibitor TAS4464 in Patients with Advanced Solid Tumors","volume":"39","author":"Yamamoto","year":"2021","journal-title":"Investig. New Drugs"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"103607","DOI":"10.1016\/j.drudis.2023.103607","article-title":"Dual-Target Inhibitors of PARP1 in Cancer Therapy: A Drug Discovery Perspective","volume":"28","author":"Zhang","year":"2023","journal-title":"Drug Discov. Today"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1021\/acs.jmedchem.7b01455","article-title":"High-Affinity Peptidomimetic Inhibitors of the DCN1-UBC12 Protein-Protein Interaction","volume":"61","author":"Zhou","year":"2018","journal-title":"J. Med. Chem."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"e181062","DOI":"10.1172\/JCI181062","article-title":"BRCAness, DNA Gaps, and Gain and Loss of PARP Inhibitor\u2013Induced Synthetic Lethality","volume":"134","author":"Li","year":"2024","journal-title":"J. Clin. Investig."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1158\/0008-5472.CAN-11-2866","article-title":"Radiosensitization of Human Pancreatic Cancer Cells by MLN4924, an Investigational NEDD8-Activating Enzyme Inhibitor","volume":"72","author":"Wei","year":"2012","journal-title":"Cancer Res."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s13073-023-01239-7","article-title":"Multi-Scale Characterisation of Homologous Recombination Deficiency in Breast Cancer","volume":"15","author":"Jacobson","year":"2023","journal-title":"Genome Med."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41586-018-0340-7","article-title":"The Shieldin Complex Mediates 53BP1-Dependent DNA Repair","volume":"560","author":"Noordermeer","year":"2018","journal-title":"Nature"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1038\/s41467-023-37537-2","article-title":"Homologous Recombination Deficiency Derived from Whole-Genome Sequencing Predicts Platinum Response in Triple-Negative Breast Cancers","volume":"14","author":"Moser","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1146\/annurev-cancerbio-061421-020411","article-title":"Rationales for Combining Therapies to Treat Cancer: Independent Action, Response Correlation, and Collateral Sensitivity Versus Synergy","volume":"7","author":"Schmidt","year":"2023","journal-title":"Annu. Rev. Cancer Biol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s13073-024-01370-z","article-title":"The PARP1 Selective Inhibitor Saruparib (AZD5305) Elicits Potent and Durable Antitumor Activity in Patient-Derived BRCA1\/2-Associated Cancer Models","volume":"16","author":"Staniszewska","year":"2024","journal-title":"Genome Med."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"4724","DOI":"10.1158\/1078-0432.CCR-22-0301","article-title":"Preclinical Characterization of AZD5305, A Next-Generation, Highly Selective PARP1 Inhibitor and Trapper","volume":"28","author":"Illuzzi","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1097\/CCO.0000000000000867","article-title":"Targeting the DNA Damage Response beyond Poly(ADP-Ribose) Polymerase Inhibitors: Novel Agents and Rational Combinations","volume":"34","author":"Ngoi","year":"2022","journal-title":"Curr. Opin. Oncol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1146\/annurev-pharmtox-040323-040828","article-title":"Artificial Intelligence for Drug Discovery: Are We There Yet?","volume":"64","author":"Hasselgren","year":"2024","journal-title":"Annu. Rev. Pharmacol. Toxicol."}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/31\/13\/2303\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T05:13:22Z","timestamp":1783055602000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/31\/13\/2303"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":130,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["molecules31132303"],"URL":"https:\/\/doi.org\/10.3390\/molecules31132303","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,1]]}}}